FDA will move to zero clinical trial model given enough Bayesian/computational evidence
Predictor: Alex Wissner-Gross · ep#242 "Elon Enters the Chip Race, the S&P 500 Repricing, and Human Drivers Will Become Illegal | EP #242" · source
Prediction text
FDA will move to zero clinical trial model given enough Bayesian/computational evidence | I think we would see similar developments from the FDA to go to a zero clinical trial model given enough Bayesian evidence and given enough computational evidence
Verbatim quote
I think we would see similar developments from the FDA to go to a zero clinical trial model given enough Bayesian evidence and given enough computational evidence
Predictor: Alex Wissner-Gross
Calibration plot (stated vs observed)
Evidence about this node from Alex Wissner-Gross is multiplied by κ in /api/intake. Lower κ = less weight; floors at 0.10 (effectively silenced) and caps at 1.00 (full weight).
Reference class: fda_breakthrough_label
FDA breakthrough designation → approval within 4 years
Tetlock-style outside view: at TRF=1 (just predicted), outside view dominates (w_in=0.3). At TRF=0 (deadline), inside view dominates (w_in=1.0). The blend regularizes overconfident inside views toward the historical base rate.
Probability over time
Milestone chain
- 2026-01-31hitFDA + EMA publish joint Guiding Principles of Good AI Practice (Jan 2026)How: CDER co-publishes 10 Guiding Principles for AI in drug development with EMASource: deep_research_enrichedconf 92%
- 2026-03-31hitEMA issues first qualification opinion on an AI-methodology virtual control armHow: European Medicines Agency formally qualifies an AI digital-twin methodology for use in pivotal trialsSource: deep_research_enrichedconf 82%
- 2026-04-15hitSanofi or peer eliminates a Phase 2 cohort in a regulatory submission using virtual patient modelsHow: Top-20 pharma sponsor publicly confirms Phase 2 was conducted with AI virtual control arm in lieu of placebo cohortSource: deep_research_enrichedconf 75%
- 2027-01-01 → 2028-12-31pendingFirst FDA pivotal approval where Phase 3 control arm is fully replaced by digital twinHow: FDA grants approval based on a Phase 3 with no concurrent placebo arm (only AI/Bayesian historical controls)Source: deep_research_enrichedconf 50%
- 2029-01-01 → 2031-09-30pendingFirst sub-indication approved with zero traditional clinical trials (computational + Bayesian only)How: FDA grants narrow indication approval whose primary evidence package is fully in-silico (digital twin + Bayesian RWE)Source: deep_research_enrichedconf 30%
What if this resolves?
Click a button to clamp this prediction and run a Gibbs sample. Returns the predictions whose marginals shift most. ~30s per run; ideal for stress-testing "if X resolves, what else moves?"
Evidence chain
Network propagation neighbors
Top incoming (parents)
Edges that influence THIS node's belief
| Kind | Node | Their prob | P(c|s=T) | P(c|s=F) | Δ implied |
|---|---|---|---|---|---|
| killer | TK09 Energy Grid Cap (Data Center Power Wall) | 35.0% | 0.050 | 0.450 | -0.054 |
| killer | TK03 AI Regulatory Moratorium (EU/US Capability Freeze) | 10.0% | 0.050 | 0.450 | +0.046 |
| prereq | SEM_015 Nvidia agreed to remit 15% of China chip-sale revenue direct — Jensen Huang | 66.3% | 0.450 | 0.050 | -0.045 |
| prereq | SEM_027 Nvidia Data Center revenue +66% YoY, contributing ~90% of $5 — Joseph Moore | 68.3% | 0.450 | 0.050 | -0.045 |
| killer | TK02 AI Compute Supply Shock (TSMC/Taiwan Disruption) | 12.0% | 0.050 | 0.450 | +0.038 |
Top outgoing (children)
Predictions THIS node influences
| Kind | Node | Their prob | P(c|s=T) | P(c|s=F) | Δ implied |
|---|---|---|---|---|---|
| prereq | 230_024 Under a certain age (40-50) life expectancy is infinity due — Dave Blundin | 39.6% | 0.600 | 0.050 | -0.146 |
| prereq | 242_023 World will have 10x more wealth around 2034-2036 — Dave Blundin | 34.2% | 0.600 | 0.050 | -0.092 |
| prereq | 246_016 Dragonfly nuclear-powered octicopter arrives at Titan in 203 — Peter Diamandis | 35.6% | 0.650 | 0.050 | -0.088 |
| prereq | 230_020 Peter's 14-year-old son Milan will never get a driver's lice — Peter Diamandis | 34.7% | 0.650 | 0.050 | -0.079 |
| prereq | 240_036 TEPCO's restarted reactor will support 20% of Japan's electr — Peter Diamandis | 34.3% | 0.650 | 0.050 | -0.075 |
Ticker exposure
Beneficiaries (24)
Adverse (6)
Prerequisites (10)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| prereq | SEM_011 | Nvidia became the world's first $5 trillion company (late 2025), operating a near-monopoly on advanced AI chips. | Capital Markets | — |
| prereq | SEM_027 | Nvidia Data Center revenue +66% YoY, contributing ~90% of $57B fiscal Q3 revenue; >$4.5T market cap entirely underpinned by AI silicon. | Capital Markets | — |
| prereq | SEM_014 | Nvidia's Arizona-based TSMC factory successfully fabricated cutting-edge semiconductors on US soil for first time in decades (October 2025). | Manufacturing | — |
| prereq | SEM_012 | Nvidia quadrupled chip production output while only doubling human headcount — achieved by deploying AI coding tools (Cursor, Claude Code) across engineering. | AI/Manufacturing | — |
| prereq | SEM_015 | Nvidia agreed to remit 15% of China chip-sale revenue directly to US government in exchange for reversing specific AI chip export bans. | Policy/Semis | — |
| killer | TK09 | Energy Grid Cap (Data Center Power Wall) | — | — |
| killer | TK05 | Rate Regime Persistence (10y > 5% through 2028) | — | — |
| killer | TK01 | AGI Capability Plateau (2026-27 Training Stall) | — | — |
| killer | TK02 | AI Compute Supply Shock (TSMC/Taiwan Disruption) | — | — |
| killer | TK03 | AI Regulatory Moratorium (EU/US Capability Freeze) | — | — |
Dependents (5)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| prereq | 230_020 | Peter's 14-year-old son Milan will never get a driver's license. | Auto/Transport | — |
| prereq | 246_016 | Dragonfly nuclear-powered octicopter arrives at Titan in 2034. | Space | — |
| prereq | 240_036 | TEPCO's restarted reactor will support 20% of Japan's electric needs by 2040 | Energy | — |
| prereq | 242_023 | World will have 10x more wealth around 2034-2036 | Macro/Economy | — |
| prereq | 230_024 | Under a certain age (40-50) life expectancy is infinity due to longevity escape velocity. | Biotech/Longevity | — |
Linked documents (10)
| Sim | Source | Title | Market prob | Polarity | Reviewed | Published |
|---|---|---|---|---|---|---|
| 0.666 | fda | FDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD V | — | mentions | pending | 2026-04-16 |
| 0.663 | arxiv | Optimizing Social Utility in Sequential Experiments | — | mentions | pending | 2026-05-07 |
| 0.662 | arxiv | Uncertainty-Aware Prediction of Lung Tumor Growth from Sparse Longitudinal CT Data via Bayesian Physics-Informed Neural Networks | — | mentions | pending | 2026-05-13 |
| 0.660 | fda | FDA ANDA213405: LENALIDOMIDE (LENALIDOMIDE) — TORRENT | — | mentions | pending | 2026-04-27 |
| 0.659 | fda | FDA ANDA215356: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUROBINDO PHARMA LTD | — | mentions | pending | 2026-06-03 |
| 0.658 | fda | FDA ANDA212414: LENALIDOMIDE (LENALIDOMIDE) — HETERO LABS LTD V | — | mentions | pending | 2026-04-27 |
| 0.653 | fda | FDA ANDA212336: ANDA212336 ((unspecified)) — DR REDDYS LABS LTD | — | mentions | pending | 2026-05-07 |
| 0.652 | fda | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | — | mentions | pending | 2026-06-03 |
| 0.648 | fda | FDA NDA021880: REVLIMID (LENALIDOMIDE) — BRISTOL MYERS SQUIBB | — | mentions | pending | 2026-04-27 |
| 0.647 | fda | FDA ANDA204345: CAPECITABINE (CAPECITABINE) — DR REDDYS | — | mentions | pending | 2026-05-07 |
Raw metadata
{
"nia": false,
"qty": "0 clinical trials",
"url": "https://www.youtube.com/watch?v=wMLcIWLlcWg",
"mode": "PREDICTION",
"role": "Host",
"caveats": "barring exceptional circumstance",
"context": "the FDA to go to a zero clinical trial model given enough Bayesian evidence",
"to_year": 2031,
"verbatim": "I think we would see similar developments from the FDA to go to a zero clinical trial model given enough Bayesian evidence and given enough computational evidence",
"conv_cues": "I think",
"direction": "HAPPEN",
"from_year": 2026,
"timeframe": "~5 years",
"conv_level": "MEDIUM",
"milestones": [
{
"kind": "llm_pre_event",
"label": "FDA + EMA publish joint Guiding Principles of Good AI Practice (Jan 2026)",
"source": "deep_research_enriched",
"status": "hit",
"weight": 0.4,
"ordinal": -9,
"source_id": null,
"confidence": 0.92,
"source_url": "https://www.appliedclinicaltrialsonline.com/view/understanding-fda-ema-guidance-ai-digital-twin-applications-trials",
"expected_date": "2026-01-31",
"observed_date": "2026-01-31",
"research_origin": "deep_research",
"measurement_criterion": "CDER co-publishes 10 Guiding Principles for AI in drug development with EMA"
},
{
"kind": "llm_pre_event",
"label": "EMA issues first qualification opinion on an AI-methodology virtual control arm",
"source": "deep_research_enriched",
"status": "hit",
"weight": 0.4,
"ordinal": -8,
"source_id": null,
"confidence": 0.82,
"source_url": "https://www.pienomial.com/blog/digital-twins-in-clinical-trials-how-ai-generated-virtual-control-arms-are-rewriting-study-design-in-2026",
"expected_date": "2026-03-31",
"observed_date": "2026-03-31",
"research_origin": "deep_research",
"measurement_criterion": "European Medicines Agency formally qualifies an AI digital-twin methodology for use in pivotal trials"
},
{
"kind": "llm_pre_event",
"label": "Sanofi or peer eliminates a Phase 2 cohort in a regulatory submission using virtual patient models",
"source": "deep_research_enriched",
"status": "hit",
"weight": 0.4,
"ordinal": -7,
"source_id": null,
"confidence": 0.75,
"source_url": "https://intuitionlabs.ai/articles/digital-twins-clinical-trials-virtual-control-arms",
"expected_date": "2026-04-15",
"observed_date": "2026-04-15",
"research_origin": "deep_research",
"measurement_criterion": "Top-20 pharma sponsor publicly confirms Phase 2 was conducted with AI virtual control arm in lieu of placebo cohort"
},
{
"kind": "prereq",
"label": "Nvidia became the world's first $5 trillion company (late 2025), operating a near-monopoly on advanced AI chips.",
"status": "hit",
"weight": 0.5,
"ordinal": -6,
"source_id": "SEM_011",
"expected_date": "2026-04-29",
"observed_date": "2026-04-29"
},
{
"kind": "prereq",
"label": "Nvidia Data Center revenue +66% YoY, contributing ~90% of $57B fiscal Q3 revenue; >$4.5T market cap entirely underpinned by AI silicon.",
"status": "hit",
"weight": 0.5,
"ordinal": -5,
"source_id": "SEM_027",
"expected_date": "2026-04-29",
"observed_date": "2026-04-29"
},
{
"kind": "prereq",
"label": "Nvidia's Arizona-based TSMC factory successfully fabricated cutting-edge semiconductors on US soil for first time in decades (October 2025).",
"status": "hit",
"weight": 0.5,
"ordinal": -4,
"source_id": "SEM_014",
"expected_date": "2026-04-29",
"observed_date": "2026-04-29"
},
{
"kind": "prereq",
"label": "Nvidia quadrupled chip production output while only doubling human headcount — achieved by deploying AI coding tools (Cursor, Claude Code) a",
"status": "hit",
"weight": 0.5,
"ordinal": -
... (truncated)